Navigation Links
DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing
Date:10/2/2008

- Dr. Robert Weiss, Director of Maryland Laser, Skin and Vein Institute, Introduces DOT Therapy to his practice -

BALTIMORE, Oct. 2 /PRNewswire/ -- Robert Weiss, M.D., board certified dermatologist, is among the first physicians in the U.S. to offer his patients DOT Therapy (Dermal Optical Thermolysis), the latest, state-of-the-art procedure in laser skin resurfacing. Dr. Weiss is an internationally renowned dermatologist, who is in private practice in Hunt Valley, Md. and is also Director, Maryland Laser, Skin and Vein Institute.

According to Dr. Weiss, "DOT Therapy is a highly effective tool for reversing signs of aging of the skin. The key is in the way the engineers have designed the laser application for the skin. And, skin numbing cream is all that is needed."

DOT Therapy has taken laser skin rejuvenation to a whole new level.

-- This new procedure precisely delivers CO2 laser energy targeting the

face, neck, decolletage, hand and arms, opening up whole new areas for

laser rejuvenation.

-- DOT Therapy effectively improves sun damage, brown spots, wrinkles, fine

lines, and acne scarring with little downtime or discomfort -- usually

in minutes.

-- Patients are pleased with the face and body skin tightening and

improvement of crepe skin.

-- The SmartXide DOT laser system has the unique capability to deliver a

customized pattern of tiny, micro-sized dots, rather than treating the

entire skin surface, so healing is fast.

DOT Therapy has been introduced through an alliance between Eclipsemed, Ltd., one of the country's leading aesthetic laser distributors, and DEKA, one of the world's largest laser manufacturers. The SmartXide DOT system is an advanced CO2 (carbon dioxide) laser. The CO2 laser is the most common type of laser used for skin resurfacing: thoroughly proven and tested. CO2 lasers of the past covered the entire surface of the skin, resulting in a significant amount of downtime to heal, discomfort for the patient and prolonged redness of the skin. In addition, the old CO2 lasers could not treat non-facial areas like the neck and decolletage easily because skin in these areas did not heal as well as the face. DOT Therapy has received clearance from the Food & Drug Administration.

For more information, please visit http://www.dottherapy.com or http://www.eclipsemed.com.

Press Contact: Wendy Maurice, wendy@trentandcompany.com

Marketing Contact: Michelle Peters, mpeters@eclipsemed.com


'/>"/>
SOURCE Eclipsemed, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
2. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
5. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
6. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
7. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
8. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
9. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
Breaking Medicine Technology:
(Date:5/26/2017)... Plano, Texas (PRWEB) , ... May 26, 2017 , ... ... Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita ... , “We are pleased to be the first in Arkansas to introduce the ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... ... Water damage to the flooring of several classrooms at The Fort Lee Elementary ... number of critical issues to address before students could return to classes. , First, ... no disruption to class schedules. Second, the project had to comply with New Jersey ...
Breaking Medicine News(10 mins):